Dermata Therapeutics, Inc.

DRMA • Biotechnology

$0.87

▲ +0.01 (+1.16%)

Precio actual

ResultadosÚltimo reporte: 30 jun 2026

PERFIL DE MAYOR RIESGOPrecauciónConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Conviene actuar con cautela. Los ratios recientes muestran debilidades que pueden limitar el retorno si los fundamentales no mejoran.

Capitalización

$3.50M

Crecimiento

—

Flujo de caja

0/5

Tendencia

Negative

Evidencia

Nivel de deuda manejable · 0Liquidez saludable · 4.79Rentabilidad débil

Datos financieros hasta: 30 jun 2026, 12:00 a.m. UTCÚltima actualización de earnings: 30 jun 2026, 12:00 a.m. UTCÚltima actualización del perfil: 20 ago 2026, 12:24 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$0.87

Change1.16%

Shares Out4.02M

Market Cap$3.50M

Enterprise Value$-913.90K

52W Range0.95 - 6.22

Beta0.66

P/E-0.42

P/B1.00

P/FCF-0.43

EV/EBITDA0.11

EV/FCF0.11

Price$0.87

Change1.16%

Shares Out4.02M

Market Cap$3.50M

Enterprise Value$-913.90K

52W Range0.95 - 6.22

Beta0.66

P/E-0.42

P/B1.00

P/FCF-0.43

EV/EBITDA0.11

EV/FCF0.11

Earnings Yield-239.18%

FCF Yield-232.79%

Dividend Yield0.00%

Gross Margin0.00%

Oper. Margin0.00%

Profit Margin0.00%

Debt/Eq0.00

Current Ratio4.79

Quick Ratio4.79

Target$6.00

Target Upside589.73%

Target Median$6.00

Target Range6.00 - 6.00

Volume141.81K

Avg Volume73.51K

EPS Surprise0.05

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

22/100

Fortaleza financiera

Deuda, caja, estabilidad

70/100

Potencial de crecimiento

Ingresos y expansión

50/100

Atractivo del precio

Barata o cara hoy

95/100

Por qué este puntaje▼

Nivel de deuda manejable · 0Liquidez saludable · 4.79Rentabilidad débil

Analyst view

Analyst sentiment and price target

DRMA

Analyst sentiment

Based on 1 analyst votes · 2026-10-21

100/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-20

Bajo

$6.00

Promedio

$6.00

Mediana

$6.00

Alto

$6.00

Resumen de la compañía

IPO: 8/13/2021

Industria: Biotechnology

P/B i: 1.00

Deuda / Patrimonio i: 0.00

Margen operativo: 0.00%

Margen neto: 0.00%

ROE i: -

ROIC: -

Salud financiera

Puntaje14 / 20

Deuda / Patrimonio: 0.00

Ratio corriente: 4.79

Ratio rápido: 4.79

Estado: Good

Transacciones internas

Actividad reciente de ejecutivos e insiders

Van Hoose Kyri K.

Transacción: 08/16/2026

COMPRA

Cambio

+102,040

Precio

$1.47

Presentación

08/18/2026

Tipo

COMPRA

Van Hoose Kyri K.

Transacción: 08/16/2026

COMPRA

Cambio

+102,040

Precio

$1.47

Presentación

08/18/2026

Tipo

COMPRA

Van Hoose Kyri K.

Transacción: 08/16/2026

COMPRA

Cambio

+102,040

Precio

Not reported

Presentación

08/18/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
Van Hoose Kyri K.	COMPRA	+102,040	$1.47	08/16/2026	08/18/2026
Van Hoose Kyri K.	COMPRA	+102,040	$1.47	08/16/2026	08/18/2026
Van Hoose Kyri K.	COMPRA	+102,040	Not reported	08/16/2026	08/18/2026
PROEHL GERALD T	COMPRA	+170,068	Not reported	08/16/2026	08/18/2026
PROEHL GERALD T	COMPRA	+170,068	$1.47	08/16/2026	08/18/2026
PROEHL GERALD T	COMPRA	+170,068	$1.47	08/16/2026	08/18/2026
PROEHL GERALD T	COMPRA	+1,360,544	$0.00	08/16/2026	08/18/2026
Scott Kathleen D.	VENTA	-11	$1.19	06/16/2026	06/16/2026
Bedoya-Toro Munera Maria E	COMPRA	+1,000	$1.27	02/17/2026	03/17/2026
FISHER MARY	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
Bradrick Brittany	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
Mento Steven J	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
Van Hoose Kyri K.	COMPRA	+18,000	$2.18	01/02/2026	01/06/2026
Sandler Andrew Seth	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
Nardo Christopher J.	COMPRA	+18,000	$2.18	01/02/2026	01/06/2026
Scott Kathleen D.	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
Bedoya-Toro Munera Maria E	COMPRA	+9,000	$2.18	01/02/2026	01/06/2026
WIERENGA WENDELL	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
HALE DAVID F	COMPRA	+2,500	$2.18	01/02/2026	01/06/2026
PROEHL GERALD T	COMPRA	+37,500	$2.18	01/02/2026	01/06/2026

Sobre la compañía

Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise, concentrating its efforts on discovering, advancing, and bringing to market novel pharmaceutical treatments designed to address various medical and cosmetic skin ailments. The company's principal experimental drug, DMT310, has successfully finished Phase IIb clinical trials for moderate-to-severe acne and completed a Phase Ib proof-of-concept study for mild-to-moderate psoriasis. Furthermore, DMT310 is presently undergoing Phase 2 clinical evaluation for moderate-to-severe rosacea. Dermata is also progressing with DMT410, which has concluded Phase Ib proof-of-concept trials aimed at managing hyperhidrosis and other aesthetic concerns. Established in 2014, the firm maintains its headquarters in San Diego, California.

Fuente - Link

Competidores

ARTL ATXI CARM ELAB GTBP LIPO PBM REVB VRAX WINT

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Dermata Therapeutics Announces Positive Topline Results from Cosmetic Study Evaluating Its Tome Foundational Treatment

- Once-weekly Tome Foundational Treatment demonstrated improvements across key measures of skin appearance after four treatments - - Over 71% of study participants were graded as having overall improvements in their skin after only one treatment - - Tome Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time - SAN DIEGO, CA / ACCESS Newswire / October 15, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced positive topline results from its recently completed cosmetic clinical study evaluating Tome Foundational Treatment, the Company's recently launched once-weekly skin renewal treatment. Tome Foundational Treatment is now available for purchase at www.tomeskincare.com either as a one-time purchase of four weekly treatments or through a subscription program at a discounted price.

Accesswire

Dermata Therapeutics Announces Commercial Launch of Tome Foundational Treatment

- Tome Foundational Treatment, powered by Bioneedle™, is now available for purchase at www.tomeskincare.com - - Once-weekly Foundational Treatment is designed to renew the appearance of skin and improve tone and texture over time - - Consumers can purchase a one-month kit or subscribe for convenient recurring delivery - SAN DIEGO, CA / ACCESS Newswire / August 25, 2026 / Dermata Therapeutics, Inc. (Nasdaq:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced the official commercial launch of the Tome Foundational Treatment, the first product available for purchase under the Company's Tome skincare brand. The Foundational Treatment is now available for immediate purchase at www.tomeskincare.com, either as a one-time purchase or through a monthly subscription at a discounted price.

Accesswire

Dermata Announces Preorders Now Open for Tome Foundational Treatment Ahead of Commercial Launch

- Preorders can be made by visiting www.tomeskincare.com - - Dermata is ready to begin shipping orders on the expected launch date of August 25, 2026 - - Tome Foundational Treatment is a once-weekly topical mask for skin renewal - SAN DIEGO, CA / ACCESS Newswire / August 21, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today announced that Tome Foundational Treatment, the Company's first direct-to-consumer skincare product, is now open to preorders. The Tome Foundational Treatment is expected to start shipping on August 25, 2026.

Accesswire

Dermata Therapeutics Announces $3.4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

$3.4 million upfront with up to approximately $6.7 million of potential additional gross proceeds upon the exercise in full of warrants SAN DIEGO, CA / ACCESS Newswire / August 17, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today announced that it has entered into definitive agreements for the issuance and sale of an aggregate of 2,293,608 shares of common stock (or pre-funded warrants in lieu thereof), series E warrants to purchase up to 2,293,608 shares of common stock and short-term series F warrants to purchase up to 2,293,608 shares of common stock at a purchase price of $1.46 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants in a private placement priced at-the-market under the rules of the Nasdaq Stock Market. The series E warrants and the series F warrants will have an exercise price of $1.46 per share and will be exercisable beginning on the effective date of stockholder approval of the issuance of the shares issuable upon exercise of the warrants.

Accesswire

Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the Second Quarter 2026

- Dermata announced the launch date of its first commercial product, Tome™ Foundational Treatment, expected on August 25, 2026 - - Dermata recently attended Be+Well Beauty and Wellness Show in Las Vegas, NV to announce the Tome brand - SAN DIEGO, CA / ACCESS Newswire / August 11, 2026 / Dermata Therapeutics, Inc. (NASDAQ:DRMA) ("Dermata," or the "Company"), a science-driven leader in dermatologic solutions, today highlighted recent corporate progress and reported financial results for the second quarter ended June 30, 2026. "Over the past year, we have transformed Dermata through a strategic pivot to become a commercial-stage, direct-to-consumer skincare company," commented Gerry Proehl, Dermata's Chairman, President, and CEO.

Accesswire

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-13	-0.53	-0.48	0.05
2026-03-26	-1.54	-1.52	0.02
2025-11-14	-1.59	-1.65	-0.06
2025-08-13	-2.9	-1.66	1.24
2025-05-14	-0.45	-4.5	-4.05
2025-03-17	-1.5	-3.15	-1.65
2024-11-13	-2.64	-2.04	0.6
2024-08-07	-3.79	-4.18	-0.39
2024-05-15	-5.4	-7.05	-1.65
2024-03-21	-0.78	-3.15	-2.37
2023-11-09	-0.63	-8.1	-7.47
2023-08-10	-0.92	-9.45	-8.53